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Immunological defense depends on the ability of the innate immune system to 
recognize invading microbes as foreign and thus eliminate them. The Toll-like 
receptors (TLRs) help detect foreign invaders by sensing various pathogen-
associated molecules, including microbial RNA and DNA. At present, it is 
unclear whether and how the immune system distinguishes between microbial 
and self nucleic acids, as host-derived RNA and DNA also stimulate TLRs. In 
addition, recent studies have revealed the existence of TLR-independent 
pathways that are activated in response to microbial and host nucleic acids.
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TLR recognition of RNA and DNA
The innate immune system relies on 
germline-encoded receptors to sense 
pathogen-derived molecules that are 
absent in the host. To do this, the innate 
immune system encodes 11 members of 
the Toll-like receptor family, each of 
which senses a distinct set of microbial 
products. Two major signaling path-
ways are activated upon ligand-driven 
TLR dimerization. One pathway re-
quires the adaptor molecule MyD88 
and culminates in the production of 
type I interferons (IFNs) or NF-κB–de-
pendent proinfl  ammatory cytokines in-
cluding TNF and interleukin (IL)-12. 
The other pathway requires the adaptor 
molecule TRIF and primarily culmi-
nates in the production of type I IFNs.
In macrophages and dendritic cells 
(DCs), TLRs that recognize nucleic 
acids are expressed exclusively in endo-
somes. These include TLR3, TLR7/8, 
and TLR9, which sense double-stranded 
(ds)RNA, single-stranded (ss)RNA, and 
ssDNA, respectively. Other TLRs, in 
contrast, reside on the cell membrane. 
These include TLR2, TLR4, TLR5, 
and TLR11, which recognize lipopep-
tides, lipopolysaccharide, fl  agellin,  and 
propellin, respectively (Fig. 1) (1–3). 
As TLRs are type I transmembrane 
proteins, they are likely to sample their 
specifi  c ligands within either the extra-
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cellular space or the endosomal lumi-
nal space. For endosomally expressed 
TLRs, this poses the topological prob-
lem of whether and how the appropri-
ate ligands are effi   ciently  translocated 
from the extracellular space to intracel-
lular endosomes (via receptor-mediated 
endocytosis or during viral infection), 
and how this aff   ects the respective 
TLR specifi   city. For example, in vi-
tro exposure to ssDNA oligonucleo-
tides containing CpG motifs activates 
TLR9-positive macrophages and DCs, 
and this stimulatory activity is lost when 
cytosine residues in the oligonucleotide 
are methylated, or when the internal 
CG dinucleotides are inverted to GC 
(4). However, if these apparently in-
active DNA molecules are formulated 
within cationic liposomes, which en-
hance endosomal translocation (5), and 
perhaps retain the ligand–TLR9 com-
plex in the endosomal compartment 
(6), these otherwise inactive DNA 
molecules become immunostimulatory 
and trigger robust TLR9-dependent 
cytokine production (5, 7). In support 
of this fi   nding, binding studies using 
surface plasmon resonance technology 
(Biacore) show that TLR9 binds with 
low affi   nity to ssDNA molecules that 
contain phosphodiester (PD) bonds, 
but lack canonical CpG-motifs (PD-
DNA) (8). In this reductionistic system, 
TLR9 binding is strongly enhanced 
if the concentration of the respec-
tive oligonucleotide is increased (7). A 
likely interpretation of these results is 
that high concentrations of endosomal 
ssPD-DNA, or other nonstimulatory 
oligonucleotides, can activate TLR9 in 
a CpG-independent fashion.
TLR7 and TLR8 have recently 
been shown to recognize viral or syn-
thetic RNA molecules that are rich 
in GU or U sequences, provided the 
RNA is formulated within cationic 
lipids (9; 10). However, as TLR7 re-
portedly also recognizes small interfer-
ing RNA molecules (11), which do not 
have a high GU content, there must be 
mechanisms in place that prevent host-
derived ssRNA molecules from causing 
abnormal activation of innate immune 
cells via TLR7 or TLR8. Rapid deg-
radation of endogenous RNA by RN-
ases and the topology of endosomal 
TLR expression are two likely secu-
rity mechanisms. However, the most 
important security mechanism may be 
the fact that most host-derived ssRNA 
molecules contain a high frequency of 
modifi  ed nucleotides—such as 5-meth-
ylcytidine or pseudouridine—that ren-
der them nonstimulatory (12). Of note, 
such modifications also affect TLR3 
signaling in response to viral dsRNA 
molecules, which normally triggers 
type I IFN production via the adap-
tor molecule TRIF. Whereas the pres-
ence of pseudouridine—which stabilizes 
RNA duplex formation—does not af-
fect TLR3 recognition, the presence of 
N6-methyladenosine—which destabi-
lizes RNA duplexes—dampens TLR3 
recognition (12). Overall, these results 
imply that selective posttranscriptional 
nucleoside modifi   cations suppress the 
TLR3-, TLR7- and TLR8-mediated 
immunostimulatory effects of host-
  derived RNA.
TLRs and anti-DNA (and RNA) 
autoantibodies
Systemic lupus erythematosus (SLE) is 
a prototypical human autoimmune dis-
ease in which increased serum levels of 
type I IFNs correlate with disease activ-
ity and severity. The sera of SLE pa-
tients contain immune complexes (ICs) 266   TLR AND BEYOND | Hermann Wagner and Stefan Bauer
made up of either host DNA and anti-
DNA IgG molecules, or host RNA 
and anti-RNA IgG molecules. These 
anti-DNA (and RNA) ICs result from 
the loss of tolerance to a restricted set 
of nuclear self-antigens. In vitro, these 
anti-DNA ICs activate rheumatoid fac-
tor–positive (RF+) B cells via sequential 
engagement of B cell receptor (BCR) 
and TLR9. In this system, the RF+ 
BCR fi  rst recognizes the   isotype of the 
autoantibody, and this recognition trig-
gers the subsequent translocation of the 
ICs into TLR-expressing endosomes 
(13). Similarly, anti-DNA ICs that are 
translocated to endosomes via FcγRIII-
mediated (mouse) or FcγRIIa-medi-
ated (human) en  do  cytosis activate the 
TLR9-de  pendent production of cyto-
kines, including type I IFNs (14, 15). 
Interestingly, lupus-prone mice that 
lack TLR9 fail to generate anti-ds-
DNA antibodies, yet the production 
of auto-antibodies to Smith antigens is 
not aff  ected (16), suggesting that not all 
autoantibodies depend on TLR ligation 
for their generation.
Mammalian DNA can also stimulate 
cytokine production when formulated 
with cationic lipids. In this form, mam-
malian DNA has been shown to stimu-
late murine plasmacytoid (pDCs)—also 
termed natural interferon-  producing 
cells—which respond by producing 
high concentrations of type I IFNs in 
a partly TLR9–dependent fashion (5). 
Together these data imply that host 
(self) DNA can activate immune cells 
via TLR9, particularly under conditions 
of enhanced endosomal translocation. A 
similar conclusion can now be extended 
to self-RNA. ICs containing U1 small 
nuclear ribonucleotide proteins, which 
are found in a subset of SLE patients, ac-
tivate the TLR7-dependent production 
of type I IFNs and other proinfl  amma-
tory cytokines by murine pDCs (17–
20). Thus, in SLE, both self-RNA and 
self-DNA can act as ligands for TLR7 
and TLR9, respectively, provided they 
do not contain certain posttranscrip-
tional nucleoside modifi  cations.  Per-
haps enforced endosomal translocation 
of host-DNA or host-RNA is the key 
to unraveling their TLR-dependent 
immunostimulatory potential.
TLR-independent recognition of RNA 
and DNA
Although viral dsRNA is known to be 
sensed by TLR3, DCs or fi  broblasts 
that lack TLR3 still produce type I 
IFNs after intracellular introduction of 
dsRNA molecules. This TLR3-inde-
pendent induction does not require 
TRIF, but depends on the kinase TBK1 
(TANK-binding kinase-1) and the 
transcription factor IRF-3 (IFN regula-
tory factor-3) (21). In this system, the 
RNA is recognized by the cytoplasmic 
helicase domain of the helicase protein 
retinoic acid–induced gene 1 (RIG-1). 
The downstream signaling events that 
result from this recognition require the 
NH2-terminal caspase recruitment do-
main (CARD) of RIG-1, which binds 
to the adaptor molecule Cardif (also 
called IPS-1) (22, 23). Another candi-
date for the sensing of cytoplasmic 
dsRNA molecules is Mda5 (melanoma 
diff   erentiation-associated gene 5, also 
termed Helicard). Unexpectedly, RIG-1, 
but not the TLRs, plays an essential role 
in the antiviral responses of many cell 
types. In contrast, the TLR system is in-
dispensable for type I IFN pro  duction 
by pDCs. Thus, RIG-1 and the TLRs 
Figure 1.  Nucleic acid recognition pathways in innate immune cells. Both pathogen-derived 
RNA or DNA and host-derived mammalian RNA or DNA are sensed via TLR and TLR-independent 
recognition pathways. Upon endosomal translocation, viral dsRNA, microbial or mammalian ssRNA 
and ssDNA are recognized by endosomally expressed TLR3, TLR7, (8) and TLR9, respectively. After 
ligation of TLR7, TLR8, and TLR9, the adaptor molecule MyD88 is recruited and drives the produc-
tion of proinfl  ammatory cytokine genes or type 1 interferon genes. TLR3 ligation triggers type 1 
interferon genes via the adaptor protein TRIF. Viral dsRNA is also sensed by RIG-1 (retinoic acid 
inducible gene 1), which was recently shown to recruit Cardif/IPS-1, a new CARD-containing 
  adaptor protein. Cardiff /IPS-1 in turn interacts with Ikkα/β/γ kinases and thus activates IRF3. 
Mammalian DNA triggers type 1 interferon production by an ill-defi  ned signal pathway. Whether 
the dsDNA recognition receptor belongs to the RIG family is not yet known.COMMENTARY
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appear to exert their anti  viral responses 
in a cell type–specifi  c manner (24).
Mammalian DNA can also be sensed 
in a TLR-independent manner. For ex-
ample, the FcγR-mediated translocation 
of ICs from SLE patients into endosomes 
triggers type I IFN secretion, and this 
response is only partially independent of 
TLR9 and MyD88 (14). In addition, 
the production of type I IFNs in response 
to mammalian DNA formulated in cat-
ionic lipids is also partially TLR inde-
pendent (5). Finally, cells lacking TLR9 
or MyD88 produce type I IFNs in re-
sponse to herpes simplex virus infection, 
suggesting that this response is at least 
partly TLR (MyD88) independent (25). 
Altogether, these fi  ndings  corroborate 
recent data showing that transfection of 
mammalian dsDNA induces TLR-inde-
pendent antiviral responses (26).
In a recent issue, Okabe et al. pro-
vided perhaps the clearest evidence to 
date of TLR-independent recognition 
of host DNA (27). The group analyzed 
mice lacking the enzyme DNase II and 
noted that macrophages in the embry-
onic livers of these mice accumulate 
undigested DNA. As a result, these 
embryos died in feto because of exces-
sive type I IFN production (28). Back-
crossing the DNase-defi  cient mice onto 
mouse strains lacking TLR3, TLR9, 
TRIF, or MyD88 did not rescue lethal-
ity. However, backcrossing the DNase-
defi  cient mice to a strain that lacked the 
type I IFN receptor did rescue the mice 
(27), demonstrating that the IFN-trig-
gered death of the mice did not require 
DNA-specifi  c TLR signaling pathways. 
Altogether these data clearly imply that 
a cytosolic DNA receptor exists—possi-
bly a member of the RIG family (26)—
that is able to sense endogenous DNA 
that escapes lysosomal degradation.
Why do we need sensing mechanisms 
for endogenous DNA?
In mammals, DNA is actively degraded 
during various developmental processes, 
including programmed cell death (apop-
tosis), embryogenesis, and erythropoe-
sis. Under these homeostatic conditions, 
apoptotic cells are engulfed by macro-
phages and self-DNA is degraded in 
lysosomes by DNase II, thus hindering 
an infl  ammatory response to endogenous 
(“sterile”) DNA. One may speculate on 
conditions under which it might be use-
ful for the organism to sense endogenous 
DNA via TLR-dependent and TLR-
independent pathways. For example, 
it might be an advantage to sense large 
quantities of self-DNA that are released 
during massive tissue apoptosis to pro-
mote cytokine-driven tissue repair un-
der otherwise sterile conditions. Clearly 
much work remains to be done to un-
derstand the precise biological role of 
TLR-dependent and -independent rec-
ognition of self-DNA under both ho-
meostatic and autoimmune conditions.
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